eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | severe combined immunodeficiency |
| Comorbidity | C0026764|myeloma |
| Sentences | 4 |
| PubMedID- 21188144 | scid-hu mice engrafted with hg myeloma cells were treated with saline or pth for 4 weeks. |
| PubMedID- 21693026 | In contrast, the tumor sizes in the scid-rab mice inoculated with myeloma cells stably expressing the pf4 gene was significantly smaller (102.3 ± 19.8 mm3, 118.2 ± 17.9 mm3, and 144.9 ± 15.6 mm3 for u266 [figure 3b], rpmi8226, and lp-1, respectively; p < 0.05) and in those inoculated with myeloma cells stably expressing the p17-70 fragment (76.6 ± 7.9 mm3, 85.4 ± 8.2 mm3, and 87.1 ± 9.6 mm3 for u266 [figure 3c], rpmi8226, and lp-1 cells, respectively; p < 0.05), suggesting that pf4 and p17-70 attenuated the growth of the myelomas in the scid-rab mice. |
| PubMedID- 24990525 | More recently, experiments utilizing scid mice injected with human myeloma cells demonstrated that the ccr1 antagonist bx471 reduced osteolytic lesions, while the ccr1 antagonist mln-3897 prevented myeloma cell adhesion to osteoclasts. |
| PubMedID- 22425892 | As shown in figure 2a, 2b and supplementary figure 1, severe bone resorption was observed in 20 of 24 scid-hu mice injected with primary myeloma cells with high/detectable p38 activity from eight patients, while none of 12 mice injected with primary myeloma cells with undetectable pp38 (from four patients) had visible bone resorption, as detected by radiography at 8 weeks after tumor inoculation. |
Page: 1